Cytokine-based therapies for HIV infection

AIDS

Volumn 15, Issue SUPPL. 5, 2001, Pages

  Allende, M C ^a   Clifford Lane, H ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Cytokines; HIV; Immune based therapies; Interleukin 2; Vaccines

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 16; INTERLEUKIN 2; INTERLEUKIN 7; MACROGOL; ZALCITABINE; ZIDOVUDINE;

CLINICAL TRIAL; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOSTIMULATION; IMMUNOTHERAPY; LYMPHOCYTOPENIA; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REVIEW; VIRUS IMMUNITY;

CLINICAL TRIALS; CYTOKINES; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY;

EID: 0035663465     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200100005-00022     Document Type: Review

References (61)

1. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy
2. Re-emergence of HIV after stopping therapy
3. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression
4. Immune reconstitution in HIV infection
5. Evaluation of CD4+ T cell function in vivo in HIV-infected patients as measured by bacteriophage phiX174 immunization
6. Impact of HIV-1 infection and highly active antiretroviral therapy on the kinetics of CD4+ and CD8+ T cell turnover in HIV-infected patients
7. HIV-1 viremia suppresses antigen-specific proliferation despite maintenance of antigen-specific CD4+ T cells
8. Maintenance of large numbers of virus-specific CD8+ T cells in HIV-infected progressors and long-term nonprogressors
9. Alternative strategies for anti-HIV treatment
10. Interleukin-2 and the interleukin-2 receptor
11. Temporal sequence and cellular origin of interleukin-2 stimulated cytokine gene expression
12. Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome
13. Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: A randomized controlled trial
14. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons
15. Duration of proleukin IL-2 therapy is more important than total dose in achieving CD4 expansion
16. Immunotherapy of hiv-infected patients with intermittent interleukin-2: Effects of cycle frequency and cycle duration on degree of CD4(+) T-lymphocyte expansion
17. Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: A randomized, controlled, multicenter study
18. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: A randomised controlled trial
19. Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease
20. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial
21. Randomized study of intermittent subcutaneous interleukin-2 (IL-2) therapy without antiretrovirals versus no treatment
22. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus
23. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with ≤250/microL CD4 T cells and undetectable plasma virus load
24. 3: ACTG-328 - Final results at 84 weeks
25. 3 despite effective HAART
26. Apoptosis rates of T-lymphocytes in HIV patients increase during intermittent administration of interleukin-2
27. Interleukin-2 (IL-2) treatment reduces soluble CD30 (sCD30) plasma levels and the percentage of apoptotic cells in HIV infected patients
28. Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expression
29. Aggressive HAART + IL-2 is unable to induce HIV remission in early-stage disease after 18 months
30. Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs
31. Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: The role of granulocyte colony-stimulating factor
32. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: Results of a randomized, multicenter, controlled trial
33. The effect of long-term treatment with granulocyte colony-stimulating factor on hematopoiesis in HIV-infected individuals
34. Immunological and virological changes in antiretroviral naive human immunodeficiency virus infected patients randomized to G-CSF or placebo simultaneously with initiation of HAART
35. Phase III study of granulocyte-macrophage colony-stimulating factor in advanced HIV disease: Effect on infections, CD4 cell counts and HIV suppression
36. Successful treatment of aphthous ulcerations in AIDS patients using topical granulocyte-macrophage colony-stimulating factor
37. A multicenter, randomized, double-blind, placebo-controlled trial of recombinant human interleukin-10 in HIV-infected subjects
38. Dysregulation in IL-12 secretion by neutrophils from HIV-infected patients
39. Phase 1 trial of a single dose of recombinant human interleukin-12 in human immunodeficiency virus-infected patients with 100-500 CD4 ells/-g/L
40. CD40 ligand trimer and IL-12 enhance peripheral blood mononuclear cells and CD4+ T cell proliferation and production of IFN-gamma in response to p24 antigen in HIV-infected individuals: Potential contribution of anergy to HIV-specific unresponsiveness
41. Interferons and interferon (IFN)-inducible protein 10 during highly active anti-retroviral therapy (HAART)-possible immunosuppressive role of IFN-alpha in HIV infection
42. A randomized trial of interferon alpha therapy for HIV type 1 infection
43. Effect of interferon and ribavirin on HIV viral load
44. Antiretroviral activity and tolerability of PEG-Interferon alpha-2b in patients on stable background therapy: Results of a phase I/II study
45. Recombinant human gamma interferon in human immunodeficiency virus-infected children: Safety, CD4(+)-lymphocyte count, viral load, and neutrophil function (AIDS Clinical Trials Group Protocol 211)
46. Circulating interleukin-7 levels are correlated with T-lymphopenia and viral load in HIV-1-infected individuals: Implications for disease progression
47. Increasing thymic output with exogenous IL-7
48. Interleukin-15 enhances neutrophil functional activity in patients with human immunodeficiency virus infection
49. Enhanced survival and potent expansion of the natural killer cell population of HIV-infected individuals by exogenous interleukin-15
50. Effect of interleukin (IL)-15 priming on IL-12 and interferon-gamma production by pathogen-stimulated peripheral blood mononuclear cells from human immunodeficiency virus-seropositive and -seronegative donors
51. Spontaneous programmed cell death of peripheral blood mononuclear cells from HIV-infected persons is decreased with interleukin-15
52. Interleukin-15 is a potent survival factor in the prevention of spontaneous but not CD95-induced apoptosis in CD4 and CD8 T lymphocytes of HIV-infected individuals. Correlation with its ability to increase BCL-2 expression
53. Activation, survival and apoptosis of CD45RO+ and CD45RO- T cells of human immunodeficiency virus-infected individuals: Effects of interleukin-15 and comparison with interleukin-2
54. Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes
55. Role of IL-16 in HIV replication
56. Interleukin-16 (IL-16) inhibits human immunodeficiency virus replication in cells from infected subjects, and serum IL-16 levels drop with disease progression
57. Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients
58. Efficacy of low-dose intermittent subcutaneous interleukin (IL)-2 in antiviral drug-experienced human immunodeficiency virus-infected persons with detectable virus load: A controlled study of 3 il-2 regimens with antiviral drug therapy
59. 3
60. A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand
61. IL-2 therapy produces no change in HIV RNA after one year. Beirn Community Programs for Clinical Research on AIDS